Bitwise Ethereum ETF Common shares of beneficial interest (ARCA: ETHW)

Ultime notizie per Bitwise Ethereum ETF Common shares of beneficial interest (ARCA:ETHW)

The Funds principal investment strategy is to invest directly in ether (ETH). The fund enables investors to gain exposure to the price movement of ether through a traditional investment vehicle while seeking to minimize administrative costs. The Funds ether is held with one of the worlds leading crypto asset custodians.

Bitwise Ethereum Etf

Bitwise Ethereum ETF

GameStopSunrise,,Florida,,Usa:,Game,Stop,Store,Sign,In,The,Sawgrass

New ETFs

ETFs

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

COIN

ETHW

Bitwise Funds Trust Bitwise GME Option Income Strategy ETF

IGME

MSTR

Sfruttare la volatilità della più nota meme stock per un flusso di reddito. Un nuovo strumento finanziario lo rende ora possibile.

Ecco come guadagnare con le azioni GME senza &#34;mal di testa&#34;

Bitwise Ethereum ETF Common shares of beneficial interest

EthereumPoW - United States Dollar

Alpha Modus Ventures, LLC ("AMV"), a related party of Alpha Modus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>, and the "Company"))) which entered into a patent monetization agreement with the Company in April, today announced that it has filed a federal lawsuit in the United States District Court for the Western District of Texas against Rackspace US, Inc. for willful infringement of three foundational U.S. patents: 11,108,591, 11,310,077, and 11,303,473. These patents center on AMV's pioneering innovations in Fibre Channel over Ethernet (FCoE) transformation technology—advancements that enable seamless and cost-efficient convergence of storage and data networks in cloud and enterprise infrastructure.
Key claims in the Rackspace lawsuit include:
<ul>
<li>Direct and induced infringement of AMV's expired but enforceable patents</li>
<li>Willful commercial use of patented FCoE technologies without license</li>
<li>Enhanced damages sought under U.S. patent law for egregious infringement</li>
</ul>

News

AMOD

AMODW

Alpha Modus Ventures Files Federal Lawsuit In United States District Court For The Western District Of Texas Against Rackspace For Infringement Of Three Foundational U.S. Patents

JP Morgan analyst Tomohiko Sano initiates coverage on CSW Industrials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSW#NYSE">CSW</a>) with a Overweight rating and announces Price Target of $320.

Price Target

Initiation

Analyst Ratings

JP Morgan Initiates Coverage On CSW Industrials with Overweight Rating, Announces Price Target of $320

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is trading near our pivotal area of 604.45. Bullish participants ideally want to see an initial lift toward 605.41. If buyers successfully defend that point, momentum could carry SPY higher to the subsequent supportive mark at 606.34. Strength holding above this zone during regular market hours would set up further upside potential toward 607.55, with an ultimate bullish aim of reaching 608.35 today.&nbsp;
If buyers fail to maintain control at 604.45, bears will likely attempt to break through 603.38. Persistent selling could drag SPY lower, testing 602.37. Further downside pressure would target support at 601.22. A highly aggressive selling scenario today would put our bearish objective of 600.51 in play.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is currently consolidating around the critical mark of 536.95. Bulls should focus on reclaiming stability above 538.06 to validate further upward movement. Success here would encourage buyers to establish 539.02 as solid support, setting the stage for a drive toward 540.60. Sustained buying momentum could propel QQQ to challenge the 542.31 area, with an ambitious bull goal today of 543.58.
If QQQ struggles to maintain support at 536.95, bearish traders will aim to pull the market lower, initially targeting 535.30. Extended weakness would put pressure on 534.60. Should selling intensity continue, a test of 533.70 is probable, with a deeper bearish target for today&#8217;s session located at 532.52.
Apple Inc. (AAPL)
Apple is trading near our defined pivot of 204.33. Bullish traders want price stability above this area, ideally sparking a rally toward 205.54. Ongoing buying energy would likely propel the market upward, targeting 206.55. A sustained bullish drive could see Apple approach today&#8217;s ambitious bull target of 207.18.
Conversely, a loss of the 204.33 level would prompt bearish participants to aggressively push lower to test support at 203.48. Additional selling may see prices declining further toward 202.29. Heavy bearish pressure could continue, challenging 200.53, with our ultimate bearish target today placed at 199.51.
Microsoft Corp. (MSFT)
Microsoft is presently hovering near our significant level of 488.74. For bullish traders, holding firmly above this mark is essential to fuel an upward move toward 489.88. Stability at this higher level would set up bullish continuation, aiming next for 491.33. Persistent buying could push Microsoft higher to achieve today&#8217;s high-end bullish target of 493.62.&nbsp;
Failure to defend 488.74 could shift control to bearish traders, who would likely press downward, targeting initial support at 487.59. Further weakening might lead prices down toward 486.72. Sustained bearish sentiment could trigger additional selling toward 485.93, with today&#8217;s deeper bearish target resting at 484.76.
NVIDIA Corporation (NVDA)
NVIDIA is actively trading around the key threshold of 145.61. Bullish investors aim to secure a move upward to reclaim 147.06 firmly as supportive ground. Continued bullish strength would then position the market for a climb toward 148.52. Robust buying momentum could further elevate NVIDIA, approaching 150.32, with today&#8217;s optimistic bull objective at 151.99.&nbsp;
A breach below 145.61 could trigger bearish traders to target an immediate drop to 144.21. Sustained selling activity might see a deeper retreat to 143.41. Additional weakness would expose the support level at 142.35. If bearish momentum intensifies significantly today, a test of our ultimate bear target at 141.21 is expected.
Alphabet Inc Class A (GOOGL)
Alphabet is actively trading around our pivotal level of 167.04. Bulls will be focused on solidifying support here and pushing higher to achieve the upside target at 169.34. Sustained bullish momentum could fuel a further rally, approaching our bullish daily target at 171.14.&nbsp;
Should 167.04 fail to hold, bearish sellers will seek downward momentum toward 165.41. Intensified selling could further push Alphabet down to 163.79. If bearish activity persists aggressively, we anticipate a deeper move targeting today&#8217;s bearish objective of 161.79.
Meta Platforms Inc (META)
Meta is currently oscillating around the key area of 704.07. Bulls will aim to swiftly reclaim and defend 708.06 as firm support, setting the stage for advancement toward 712.14. Strong buying activity might propel price higher to challenge 714.27. Continued bullish dominance could enable Meta to approach today&#8217;s elevated bullish target of 716.39.&nbsp;
Conversely, failure to sustain the 704.07 support area would give bearish traders confidence to target an initial decline to 699.93. Persistent selling would bring further downside pressure, potentially pushing toward 695.62. Continued bearish activity might expose the lower bearish target today at 692.10.
Tesla Inc. (TSLA)
Tesla is actively trading near our crucial level of 356.80. Bulls aim to catalyze an upward movement toward 363.84. Sustained bullish energy could propel price action higher toward 370.22. Should broad market sentiment turn favorable today, buyers may aggressively lift Tesla to challenge 378.79, with today&#8217;s high-end bullish goal at 384.07.&nbsp;
On the bearish side, losing the critical level at 356.80 would likely spark selling pressure targeting 350.87. Continued bearish strength could extend downward toward 346.64. If this support level fails under heavy selling pressure, a deeper bearish scenario emerges with today&#8217;s ultimate bearish objective at 340.97.
Final Word: Today&#8217;s economic calendar is densely packed, beginning at 8:30 AM ET with the release of the Philly Fed Non-Manufacturing Activity for June, the Q1 Current Account Balance, and Canada&#8217;s May CPI report. Shortly thereafter, at 9:00 AM ET, traders will digest the FHFA House Price Index data for April. The market will receive additional guidance at 10:00 AM ET from the Richmond Fed Manufacturing Index for June and the Conference Board&#8217;s June Consumer Confidence report. The Treasury&#8217;s 2-Year Note Auction at 1:00 PM ET may also influence bond market sentiment significantly.&nbsp;
Moreover, traders must stay attentive throughout the day, as multiple Federal Reserve members are scheduled to speak, including Hammack (9:15 AM &amp; 10:15 AM ET), Williams (12:30 PM ET), Kashkari (1:45 PM ET), Collins (2:05 PM ET), and Barr (4:00 PM ET). However, the session&#8217;s pivotal event will be Federal Reserve Chair Jerome Powell&#8217;s Semi-Annual testimony before the House Financial Services Committee at 10AM ET. Additionally, escalating geopolitical tensions, particularly concerning violations of the Israel/Iran ceasefire agreement, may amplify market volatility substantially. Given these multiple influential catalysts, prudent risk management will be crucial today. Stay vigilant and trade responsibly!
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

Trading Ideas

How To Trade SPY, Top Tech Stocks Using Technical Analysis

GRNQ

GreenPro Receives Conditional Approval From Labuan Financial Services Authority To Establish And Operate An Islamic Digital Bank

Guggenheim analyst Yatin Suneja reiterates Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) with a Buy and maintains $26 price target.

Reiteration

Larimar Therapeutics, Inc. - Common Stock

LRMR

Guggenheim Reiterates Buy on Larimar Therapeutics, Maintains $26 Price Target

ELAB

PMGC Holdings To Acquire A US-Based CNC Aerospace Manufacturer With A 2024 Revenue Base Of ~$4.5M

Paychex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) will release earnings results for the fourth quarter, before the <a href="https://www.benzinga.com/quote/payx/earnings">opening bell on Wednesday, June 25.</a>
Analysts expect the Rochester, New York-based company to report quarterly earnings at $1.19 per share, on revenue of $1.42 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Paychex founder Thomas Golisano will step down from board of directors, effective after board&#8217;s July, 2025 meeting.
Paychex shares rose 1.4% to close at $151.25 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/payx/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>JP Morgan analyst Tien-Tsin-Huang maintained an Underweight rating and raised the price target from $140 to $148 on June 18, 2025. This analyst has an accuracy rate of 63%.</li>
<li>RBC Capital analyst Ashish Sabadra maintained a Sector Perform rating and boosted the price target from $148 to $165 on June 3, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Barclays analyst Ramsey El-Assal maintained an Equal-Weight rating and increased the price target from $140 to $155 on March 31, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Morgan Stanley analyst James Faucette maintained an Equal-Weight rating and raised the price target from $137 to $142 on March 27, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Citigroup analyst Peter Christiansen maintained a Neutral rating and boosted the price target from $145 to $158 on March 27, 2025. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying PAYX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PAYX/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24033521/image-347-1024x547.png" alt="" class="wp-image-959259" style="width:641px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24033521/image-347-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24033521/image-347-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24033521/image-347-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24033521/image-347.png 1156w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46050117/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Earnings

Markets

PAYX

Paychex Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) saw its stock edge higher in Tuesday&#8217;s premarket session following a significant European breakthrough in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46070261/tilray-medical-receives-italys-first-authorization-from-the-ministry-of-health-to-distribute-medic" rel="noreferrer noopener">medical cannabis sector</a>.
Tilray Medical, a division of Tilray Brands, announced a significant milestone in its European expansion with the introduction of three new medical cannabis flower varieties in Italy.
Through its wholly-owned subsidiary, FL Group, Tilray has become the first company in Italy to receive official authorization from the Ministero della Salute (Italian Ministry of Health) to import and distribute proprietary Tilray Medical-branded medical cannabis flower for therapeutic use.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44870836/vegan-sugar-free-and-now-in-australia-tilrays-edibles-arent-your-average-medical-launch" rel="noreferrer noopener">Vegan, Sugar-Free, And Now In Australia: Tilray&#8217;s Edibles Aren&#8217;t Your Average Medical Launch</a>
The launch includes three medical cannabis varieties, each with distinct cannabinoid compositions: THC 25%, THC 18%, and a balanced THC 9% / CBD 9% formula.
These products are available via pharmacies throughout Italy, supporting healthcare providers in offering more tailored cannabis-based treatment options.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray, emphasized the importance of the milestone, stating it &#8220;underscores the vital role of medical cannabis as a therapeutic medicine for patients in need.&#8221;
She also expressed appreciation for the Italian government&#8217;s support and the regulatory foundation enabling consistent access to cannabinoid therapies.
Tilray continues to scale its reach across Europe with operations in countries including Germany, Portugal, Poland, and the United Kingdom. The company&#8217;s offerings adhere to EU-GMP (Good Manufacturing Practice) certification, which ensures quality and safety standards across its product line.
The expansion into Italy further strengthens Tilray&#8217;s positioning as a frontrunner in the medical cannabis industry, aligning with its goal to empower patients and physicians with reliable and science-driven cannabinoid options.
Price Action: TLRY shares are trading higher by 2.61% to $0.3699 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-martin-northrop-grumman-among-stocks-in-focus" target="_blank" rel="noreferrer noopener">BlackRock Bets Big On Defense Companies Amid Escalating Geopolitical Tensions: Palantir, Lockheed Martin, Northrop Grumman Among Stocks In Focus</a></li>
</ul>
Photo via Shutterstock

Cannabis

Movers

General

TLRY

Tilray Makes History, First To Import And Sell Branded Medical Cannabis In Italy

Contracts

OSIS

OSI Systems Awarded $14M contract From An International Customer For Cargo And Vehicle Inspection Systems

Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities
SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in the foot and ankle fusion market.
Under the terms of the agreement, SINTX has acquired all intellectual property, product designs, and development assets related to six (6) differentiated foot and ankle implant systems. These designs are backed by clinical development and mechanical testing and a 510(k) pre-submission that is expected to accelerate near-term commercial launch activities. The global ankle fusion market, currently valued at approximately $750.5 million, is expected to grow to $1.38 billion by 2032, representing a CAGR of 9.1%, according to industry research.
"This acquisition is transformative for SINTX by adding a family of FDA-reviewed implants, portfolio of new technologies, and capital, accelerating our shift from R&amp;D to revenue generation and commercial scale," said Eric Olson, CEO of SINTX Technologies. "Additionally, the SiNAPTIC team brings deep expertise in product development, regulatory strategy, and commercialization to support our existing commercial product portfolio—key elements in driving increased value for our shareholders."
As part of the transaction, key members of the SiNAPTIC Surgical executive team and board of directors will join SINTX in the following roles:
<ul>
<li>Chairman of SINTX Clinical Advisory Board, Bryan Scheer, M.D.</li>
<li>Managing Director of Business Development, Hugh Roberts</li>
<li>Chief Commercial Officer, Lisa Marie Del Re, MPE, ATC, NASM-PES</li>
<li>Senior Vice President of Regulatory and Quality Affairs, Brian Hockett</li>
<li>Senior Design Engineer, Basil Tharu, M.S. &nbsp;</li>
</ul>
In consideration for the acquired assets, SINTX issued $750,000 in common shares , priced at $3.465 per share which represents a 10% premium to the closing price of the Company's common stock on Friday, June 20, 2025, along with 325,000 performance-based common stock purchase warrants. The common shares are subject to a six-month lock-up agreement and the Company has committed to file a resale registration statement with the Securities and Exchange Commission registering the resale of the common shares and the common shares issuable on exercise of the common stock purchase warrants. These warrants are exercisable over five years at a strike price of $6.30, and vest upon achieving specific regulatory and commercial milestones, including FDA clearance and revenue targets.
SINTX will manufacture all devices under its FDA-registered and ISO-certified quality system and leverage existing FDA clearances and Master Files to streamline regulatory approvals.
In addition, Dr. Bryan Scheer, Chairman and CEO of SiNAPTIC, will lead a newly formed Clinical Advisory Board to guide ongoing product development and surgeon engagement.

SINT

SINTX Technologies Acquires SiNAPTIC Surgical Assets Including Patented Implants; Issues $750K Shares And 325K Warrants

ASBP

ASBPW

Aspire Biopharma Announces Last Patient Dosed In Phase 1 Single-Center Clinical Study Of Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation; Topline Results Expected Mid Q3 2025

Guggenheim analyst John Heinbockel reiterates Life Time Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) with a Buy and maintains $36 price target.

Guggenheim Reiterates Buy on Life Time Group Hldgs, Maintains $36 Price Target

JP Morgan analyst Tomohiko Sano initiates coverage on Allegion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>) with a Overweight rating and announces Price Target of $170.

ALLE

JP Morgan Initiates Coverage On Allegion with Overweight Rating, Announces Price Target of $170

Guggenheim analyst Michael Schmidt reiterates ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and maintains $45 price target.

AVBP

Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target

DSS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSS#NYSE">DSS</a>) ("DSS" or the "Company"), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that its subsidiary, Impact BioMedical Inc. ("Impact"), has entered into a definitive merger agreement (the "Merger Agreement") with Dr. Ashleys Limited ("Dr. Ashleys"), a global pharmaceutical company.
Under the terms of the agreement, Dr. Ashleys will acquire Impact through a reverse merger that will result in a newly formed combined entity (the "PubCo") traded on the NYSE American under the name "Dr Ashleys Limited."
This strategic transaction marks an important milestone not only for Impact, but also for DSS, as it reflects a successful outcome in the overall Company strategy to unlock value across the portfolio and for its shareholders by advancing key subsidiaries toward independent public listings and/or other exit opportunities.

DSS' Impact BioMedical Enters Into Definitive Merger Agreement With Dr. Ashleys

Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models
Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use
FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company has submitted a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1b Dose Finding study of its Auger emitting radiopharmaceutical, CLR 125, for the treatment of relapsed TNBC. CLR 125 is an iodine-125 Auger-emitting drug candidate targeting solid tumors, such as triple negative breast, lung and colorectal cancers.

Biotech

CLRB

Cellectar Biosciences Submits FDA Protocol For Phase 1b Study Of CLR 125 In Relapsed Triple Negative Breast Cancer

Guggenheim analyst Michael Morris reiterates Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy and maintains $165 price target.

RDDT

Guggenheim Reiterates Buy on Reddit, Maintains $165 Price Target

Primech AI Pte. Ltd. ("Primech AI" or the "Company"), a subsidiary of Primech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>), today announced the signing of a strategic partnership with Hong Kong-based ReMining Ai Ltd to expand the deployment of its revolutionary HYTRON autonomous <a href="https://www.globenewswire.com/Tracker?data=iZ7fObqGU6ZnGNY5lLVfIy5XGRRitwii5kKoE1rMQzpE2lSCgnlvg_7isAYr1wcV4XtpG54CFPtbVVVp0CnWMA97q_jZfi0z6E4P3DZMylHdZAUmCQbYfHh1Y5ml1MI6ScUsyTbB6aqyb1b6hHM_wA==">bathroom cleaning robot</a> to the Hong Kong market.
The companies formally established their collaboration through a signed Memorandum of Understanding (MOU), creating a framework for ReMining Ai Ltd to serve as Primech AI's authorized agent in Hong Kong for two years.

Global

PMEC

Primech AI Partners With ReMining Ai To Launch HYTRON Autonomous Bathroom Cleaning Robot In Hong Kong

ONDS

Ondas Holdings' American Robotics Partners With Mistral, Focusing On Joint Marketing, Sales, And Integration Of Optimus Drone System And Iron Drone Raider Into US Defense And Homeland Security Markets

Quoin Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the Company's lead asset, QRX003, for the treatment of Netherton Syndrome.
The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. It follows earlier regulatory recognition by the European Medicines Agency (EMA), which granted Orphan Drug Designation to QRX003 in May 2025.

Comments

Bitwise Ethereum ETF Common shares of beneficial interest

Notizie

Ultime notizie per Bitwise Ethereum ETF Common shares of beneficial interest (ARCA:ETHW)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO